IMCRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Immunocore Holdings plc

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$29.84+0.44 (+1.50%)

Close on Oct 19, 2026

Market cap: $1.52B
P/E (TTM): –
Dividend yield: 0.00%

Immunocore Holdings plc income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Revenue	400	310	249	174	36	–	–	–
Cost of Revenue	5.09	2.73	1.04	1.09	0	–	–	–
Gross Profit	395	307	248	173	36	–	–	–
Research & Development	275	222	164	102	100	–	–	–
Selling, General & Admin	165	156	144	123	111	–	–	–
Operating Income	-45	-70	-60	-52	-175	–	–	–
Interest Expense	12	19	5.15	5.41	5.57	–	–	–
Interest & Investment Income	16	26	18	3.76	0.07	–	–	–
Other Non-Operating Income	20	14	-0.90	-1.68	-0.07	–	–	–
Asset Impairment Charges	0	0	0	0	0	–	–	–
Pretax Income	-19	-53	-61	-41	-180	–	–	–
Income Tax Expense	16	-1.85	-5.60	12	0.15	–	–	–
Net Income	-36	-51	-55	-53	-180	–	–	–
EPS (Basic)(per share)	-0.71	-1.02	-1.13	-1.15	-4.24	–	–	–
EPS (Diluted)(per share)	-0.71	-1.02	-1.13	-1.15	-4.24	–	–	–
Shares Outstanding (Basic, Weighted)(shares)	50	50	49	46	42	27	22	–
Shares Outstanding (Diluted, Weighted)(shares)	50	50	49	46	42	27	22	22
Dividend per Share(per share)	0.00	0.00	0.00	0.00	–	–	–	–
EBITDA	-42	-66	-56	-46	-167	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 98.9%
Operating margin: -5.2%
Net margin: -4.2%
Return on equity, FY2025: -9.6%

Financial strength

Current ratio: 4.47
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 206.2%

Valuation

P/E ratio: –
Price to sales: 3.53
Price to book: 3.62
Dividend yield: 0.00%